Tien Karena X, Romo Erica, Adam Murtaza K
Rocky Vista University, Parker, CO, USA.
Colorado Retina Associates, Denver, CO, USA.
J Vitreoretin Dis. 2024 Jun 22;8(5):554-557. doi: 10.1177/24741264241260093. eCollection 2024 Sep-Oct.
To describe the technique, safety profile, and outcomes of performing pars plana vitrectomy (PPV) without intravenous (IV) anesthesia. This retrospective single-surgeon study comprised patients who had PPV without IV sedation between September 2018 and April 2022. Patients elected to undergo PPV without sedation or with oral sedation via sublingual triazolam administered 30 minutes preoperatively. Sub-Tenon bupivacaine and lidocaine were administered at the initiation of each case. A circulating nurse monitored patient vitals and electrocardiogram tracings without anesthesiologist support. Adverse events (AEs), visual acuity (VA), supplemental block administration, and reoperation rates were documented. A total of 357 PPVs in 319 patients (mean age 68.75 ± 11.17 years [SD]; range, 36.82-98.57) were performed for surgical indications including vitreous floaters, intraocular lens or cataract surgery complications, retinal detachment, vitreous hemorrhage, and epiretinal membrane. Twenty-three cases were performed without sedation, and 334 were performed with oral sedation. For eyes with a follow-up longer than 1 month (n = 324), the preoperative VA of 0.68 ± 0.77 logMAR improved to 0.31 ± 0.46 logMAR postoperatively ( < .01). No intraoperative complications, systemic AEs, need to cease surgery prematurely, or conversion to IV sedation occurred. Five eyes (1.77%) required intraoperative supplemental sub-Tenon block administration, and 95% of patients who had a reoperation n = 10) or fellow-eye surgery (n = 28) requested the same method of anesthesia without IV sedation. Vitreoretinal surgery with a sub-Tenon block and oral sedation can be safely performed without the support of an anesthesiologist. Additional trials are needed to further quantify patient comfort, surgeon experience, and complication rates.
描述在无静脉麻醉情况下进行玻璃体切割术(PPV)的技术、安全性及结果。这项回顾性单术者研究纳入了2018年9月至2022年4月期间接受无静脉镇静PPV的患者。患者选择在无镇静或术前30分钟通过舌下含服三唑仑进行口服镇静的情况下接受PPV。每例手术开始时给予球周布比卡因和利多卡因。巡回护士在无麻醉医生支持的情况下监测患者生命体征和心电图。记录不良事件(AE)、视力(VA)、补充阻滞给药情况及再次手术率。319例患者共进行了357次PPV(平均年龄68.75±11.17岁[标准差];范围36.82 - 98.57岁),手术适应证包括玻璃体混浊、人工晶状体或白内障手术并发症、视网膜脱离、玻璃体积血及视网膜前膜。23例手术未使用镇静,334例手术使用了口服镇静。对于随访时间超过1个月的眼睛(n = 324),术前平均对数最小分辨角视力(logMAR)为0.68±0.77,术后改善至0.31±0.46(P < 0.01)。未发生术中并发症、全身性不良事件、需提前终止手术或转为静脉镇静的情况。5只眼(1.77%)术中需要补充球周阻滞给药,再次手术(n = 10)或对侧眼手术(n = 28)的患者中有95%要求采用相同的无静脉镇静麻醉方法。在无麻醉医生支持的情况下,采用球周阻滞和口服镇静进行玻璃体视网膜手术是安全的。需要进一步的试验来进一步量化患者舒适度、术者经验及并发症发生率。